摘要

      普氏粪杆菌是一种有益的人类肠道微生物，也是下一代益生菌的候选菌。随着益生菌目前被用于临床治疗，需要考虑其安全性和副作用。因此，有必要全面了解不同菌株的遗传多样性、功能特征和潜在风险。在本研究中，我们收集了84F的遗传信息。从多个角度进行普氏菌的全基因组分析。基于单拷贝基因、16S rRNA序列和泛基因组组成，对不同菌株进行了系统发育分析，显示了它们之间的遗传多样性。在泛基因组的蛋白质中，我们发现副簇比核心簇和特定簇对普氏F.prausnitzii菌株的主要遗传功能的贡献更大。prausnitzii的功能注释表明，只有极少数蛋白质与人类疾病有关，并且没有编码有害产物的次级代谢基因簇。同时，在马齿苋中检测到完全的脂肪酸代谢。此外，我们检测了包括抗生素耐药性基因、毒力因子和致病基因在内的有害元素，并提出了益生菌潜在风险指数（PPRI）和益生菌潜在风险评分（PPRS），将这84株菌株分为低、中、高风险组。最后，15株菌株被确定为低风险菌株，并优先用于临床应用。毫无疑问，我们的研究结果提供了对普氏F.prausnitzii的全面理解和见解，PPRI和PPRS可用于评估益生菌的潜在风险，并指导益生菌在临床应用中的应用。Faecalibacterium prausnitzii is a beneficial human gut microbe and a candidate for next-generation probiotics. With probiotics now being used in clinical treatments, concerns about their safety and side effects need to be considered. Therefore, it is essential to obtain a comprehensive understanding of the genetic diversity, functional characteristics, and potential risks of different F. prausnitzii strains. In this study, we collected the genetic information of 84 F . prausnitzii strains to conduct a pan-genome analysis with multiple perspectives. Based on single-copy genes and the sequences of 16S rRNA and the compositions of the pan-genome, different phylogenetic analyses of F. prausnitzii strains were performed, which showed the genetic diversity among them. Among the proteins of the pan-genome, we found that the accessory clusters made a greater contribution to the primary genetic functions of F. prausnitzii strains than the core and specific clusters. The functional annotations of F. prausnitzii showed that only a very small number of proteins were related to human diseases and there were no secondary metabolic gene clusters encoding harmful products. At the same time, complete fatty acid metabolism was detected in F. prausnitzii. In addition, we detected harmful elements, including antibiotic resistance genes, virulence factors, and pathogenic genes, and proposed the probiotic potential risk index (PPRI) and probiotic potential risk score (PPRS) to classify these 84 strains into low-, medium-, and high-risk groups. Finally, 15 strains were identified as low-risk strains and prioritized for clinical application. Undoubtedly, our results provide a comprehensive understanding and insight into F. prausnitzii, and PPRI and PPRS can be applied to evaluate the potential risks of probiotics in general and to guide the application of probiotics in clinical application.

https://www.frontiersin.org/articles/10.3389/fcimb.2022.919701/full?utm_source=dlvr.it&utm_medium=twitter